Clinical Trials Browser

INDUSTRY × Lymphoma × loncastuximab tesirine × Clear all

NCT04384484 2026-01-26

LOTIS 5

Phase 3 Active not recruiting

Lymphoma, Lymphoma, Large B-Cell, Diffuse

NCT05660395 2025-07-16

A Study to Evaluate the Pharmacokinetics and Safety of Loncastuximab Tesirine in Participants With Relapsed or Refractory Diffuse Large B-cell Lymphoma or High-grade B-cell Lymphoma With Hepatic Impairment (LOTIS-10)

Phase 1 Recruiting

Lymphoma, Lymphoma, Large B-Cell, Diffuse

NCT05144009 2025-01-30

LOTIS-9

Phase 2 Terminated

41 enrolled 19 charts

Lymphoma, Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse

NCT04699461 2023-10-23

LOTIS-6

Phase 2 Terminated

6 enrolled 9 charts

Lymphoma, Lymphoma, Follicular

NCT02669017 2021-05-19

Study of ADCT-402 in Patients With Relapsed or Refractory B-cell Lineage Non Hodgkin Lymphoma (B-NHL)

Phase 1 Completed

183 enrolled 38 charts

LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Waldenstrom Macroglobulinemia, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Mantle-Cell

NCT04705454 2021-05-12

Loncastixumab Tesirine (ADCT-402) Expanded Access Program (EAP) for Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma

No longer available

Lymphoma, Recurrence, Lymphoma, Large B-Cell, Diffuse